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3 About 8% to 15% of ischemic strokes are attributable to carotid atherosclerosis. [4] [5] [6] In this narrative review, we summarize the data regarding the evaluation and management of asymptomatic and symptomatic carotid stenosis.
METHODS
This review and our recommendations are supported by a formal search of the medical literature updated since a prior publication on this topic in 2007 in this journal. 7 The Appendix describes the specific approach used to identify the relevant medical literature.
IDENTIFYING AND CHARACTERIZING CAROTID STENOSIS
The most common noninvasive ways of screening for carotid stenosis are duplex ultrasonongraphy, computed tomographic angiography (CTA), and magnetic resonance angiography (MRA). In the case of carotid ultrasonography, the degree of carotid stenosis is largely determined by measuring the velocity of blood flow at various segments of the artery. Criteria have been established for translating velocity measurements into clinically useful stenosis cut points. 8, 9 For example, one meta-analysis found a peak systolic velocity of 200 cm/s or greater on ultrasonography to have a sensitivity of 90% and specificity of 94% for diagnosing angiographic stenosis of 70% or more. 8 However, measurement properties vary considerably among laboratories. Factors that can affect the sensitivity of ultrasonography include heavy calcification of the artery and selected contours of the neck. Distal and proximal segments of the extracranial carotid artery cannot be visualized on ultrasonography.
Computed tomographic angiography generally correlates well with carotid ultrasonography, although unlike ultrasonography, it exposes patients to radiation and contrast media. 10 With the recent documentation of the efficacy of mechanical thrombectomy for treating acute ischemic stroke in selected patients, 11 CTA is being used with greater frequency in the initial evaluation of patients. 12 Thus, patients with nondisabling stroke who are being considered for carotid revascularization may have a CTA available for review.
Catheter angiography traditionally has been considered the criterion standard for stenosis assessment in patients with carotid disease. However, MRA fares well by comparison. A study of 103 patients undergoing endarterectomy had their plaque sectioned transversally and assessed planimetrically. 13 All patients had preoperative catheter angiography and MRA. Overall, catheter angiography underestimated histologic stenosis by 14.5%, whereas MRA underestimated histologic stenosis by only 0.7%. Among patients with catheter angiographyedefined severe stenosis, MRA overestimated stenosis by 12.1%.
The risk associated with modern digital subtraction angiography is low. The rate of permanent neurologic complications is about 0.5%. 14 Rates of transient neurologic complications range from 0% to 2.4%, and rates of major nonneurologic complications range from 0.26% to 4.3%. 15 Nonetheless, there is little justification to expose asymptomatic patients to the risk of catheter-based angiography before treatment decisions.
The cost of carotid imaging should be considered. A prospective study of 167 patients found that the most cost-effective approach to carotid imaging for evaluating patients before endarterectomy was carotid ultrasonography and contrast-enhanced MRA, proceeding to digital subtraction angiography only in cases of discrepancy in which the MRA is positive for high-grade stenosis and the ultrasonography is negative. 16 A challenge regarding the use of revascularization for preventing stroke in patients with asymptomatic carotid stenosis is the generally low risk of stroke in untreated patients. Various imaging techniques are being used and developed to stratify risk of stroke in asymptomatic stenosis. Magnetic resonance imaging (MRI) techniques can be used to characterize plaque beyond degree of stenosis. Intraplaque hemorrhage, a lipid-rich necrotic core, and thinning and rupture of the fibrous cap predict risk of stroke. 17 Statistical modeling suggests that detection of intraplaque hemorrhage by MRI may be cost-effective for identifying asymptomatic patients most likely to benefit from carotid endarterectomy. 18 Transcranial Doppler can also stratify risk. 19, 20 The Asymptomatic Carotid Emboli Study (ACES) involving 482 patients across 26 centers found that transcranial Doppleredetected microembolic signals are associated with ipsilateral ischemic stroke in patients with asymptomatic carotid stenosis (hazard ratio, 6.37). 21 
SCREENING FOR ASYMPTOMATIC CAROTID STENOSIS
Clinically important carotid stenosis is not rare. Ultrasound studies have found the prevalence of moderate to severe atherosclerotic stenosis to range from 2% to 8% among adults in North America, Europe, and East Asia (Table 1 22-35 ). The US Preventive Services Task Force issued an updated recommendation against screening for asymptomatic carotid stenosis in the general population. 36 The Task Force raised concerns that no randomized trial has specifically documented the value of screening for carotid disease as a first step in the prevention of ischemic stroke. Further concerns were raised about false-positive detection of stenosis and of potential complications in patients undergoing revascularization. In clinical populations, carotid ultrasonography is done for diverse indications. A review of Veterans Health Administration patients who had a revascularization procedure for asymptomatic carotid stenosis found that about half had initial ultrasonography for carotid bruit or follow-up of carotid disease. 37 Several clinical features point to populations with a high pretest probability for detecting carotid stenosis on ultrasonography. Patients with peripheral artery disease (PAD) are at increased risk of having coexisting carotid stenosis. A review of Life Line Screening data from 3.67 million US adults found that the presence of PAD, defined as an anklebrachial index of less than 0.9, had a 3.28 odds ratio for detection of carotid stenosis. 38 Further, increasing severity of PAD increased the odds of carotid stenosis. Patients with ophthalmoscopic evidence of a cholesterol embolus within a retinal artery (Hollenhorst plaque) have a 13% prevalence of high-grade extracranial carotid stenosis, and patients with both Hollenhorst plaque and carotid bruit have a 37% prevalence of high-grade carotid stenosis. 39 Patients undergoing coronary artery bypass grafting at one referral center had a 38% prevalence of carotid stenosis on ultrasonography.
40 A multisociety evidencebased guideline recommended that screening for carotid stenosis could be considered for asymptomatic patients with either (1) symptomatic PAD, coronary artery disease, or atherosclerotic aortic aneurysm or (2) 2 or more of the following risk factors: 
Antiplatelet and Antithrombotic Therapy
Aspirin, the combination of aspirin and extended-release dipyridamole, and clopidogrel all have efficacy for secondary prevention of ischemic stroke in patients with noncardioembolic stroke. 43 Although long-term aspirin monotherapy is not indicated for primary stroke prevention in low-risk individuals, 42 a multisociety guideline recommends that patients with obstructive or nonobstructive extracranial carotid disease take aspirin at a daily dose of 75 to 325 mg. 44 Aspirin clearly reduces the risk of stroke in patients who have had prior ischemic stroke or transient ischemic attack (TIA). 45 However, aspirin has not been clearly proven to prevent stroke in asymptomatic patients with carotid bruit and stenosis. 46 Aspirin is recommended in asymptomatic patients with carotid stenosis to prevent coronary events. Long-term dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is not generally indicated for secondary stroke prevention because of increased risk of hemorrhage 43 and is not typically used for primary stroke prevention.
For patients undergoing revascularization, antiplatelet therapy is routinely used before and after the procedure, although the practice varies considerably depending on the nature of the revascularization procedure. In the Asymptomatic Carotid Surgery Trial (ACST)-2, survey data indicate that for patients undergoing stenting, 82% of centers used DAPT preprocedure and 86% of centers used DAPT postprocedure, with a mean postprocedure duration of 3 months. 47 For patients undergoing endarterectomy, only 31% of centers used DAPT preoperatively and 24% used DAPT postoperatively, with a mean postoperative duration of 3 months. 47 In the Vascular Quality Initiative using propensity score matching, DAPT was associated with a lower risk of stroke and a higher risk of reoperation for bleeding in patients undergoing endarterectomy. 48 When perioperative aspirin therapy is considered, more is not always better. The randomized double-blind ASA and Carotid Endarterectomy (ACE) Trial involving 2849 patients found that the rate of stroke, myocardial infarction, and death at 1 and 3 months was lower in patients taking low-dose aspirin (81 mg or 325 mg/d) compared with patients taking high-dose aspirin (650 mg to 1300 mg/d). 49 Antihypertensive Therapy Blood pressure control is essential for preventing stroke, coronary heart disease, and heart failure. 50 Trials of antihypertensive therapy at the time of an acute stroke have not reported significant effects on short-or long-term outcomes. 51, 52 Nonetheless, there remains concern that rapid lowering of blood pressure immediately following stroke in a patient with symptomatic carotid disease might increase infarct volume and worsen neurologic deficit. For asymptomatic patients, the American Heart Association strongly recommends maintaining blood pressure below 140/90 mm Hg. 44 Beyond the several hours to days following a stroke or TIA, patients with symptomatic stenosis should be treated to a target similar to that for patients with asymptomatic stenosis. 44 Lipid-Lowering Therapy Most patients with carotid stenosis will benefit from statin therapy for cholesterol lowering. Current guidelines regarding the use of statins for primary prevention focus on adjusting the intensity of therapy based on projected risk of cardiovascular disease. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial randomized patients with a low-density lipoprotein cholesterol (LDL-C) level of 100 to 190 mg/dL (to convert to mmol/L, multiply by 0.0259) within 1 to 6 months following a stroke or TIA to placebo or atorvastatin at 80 mg/d. The subgroup of patients with known carotid stenosis in the trial had a 33% reduction in all strokes and a 43% reduction in major coronary events with atorvastatin. 53 Moderate evidence supports lipid lowering with a statin to a target LDL-C level below 100 mg/dL in all patients with extracranial atherosclerotic stenosis and for those who have had symptoms, lowering to a more aggressive target LDL-C level below 70 mg/dL. 44 
Cigarette Smoking
Smoking increases the risk of stroke in a dose-dependent manner, and quitting smoking decreases the risk. 54 Smoking is also associated with the prevalence of carotid plaque. 55 Smokers should be encouraged to quit, and if necessary, drugs to assist in quitting should be prescribed. Higher pack-years increases inflammatory markers such as highly sensitive C-reactive protein in active smokers, and time from quitting in former smokers reduces inflammatory markers as well as subclinical vascular disease, including carotid disease. 56 
Interventions for Other Risk Factors
Increasing regular physical activity should be encouraged in patients with carotid atherosclerosis. In a study involving more than 3 million carotid ultrasound tests, the intensity of self-reported physical activity was associated with lower odds of carotid atherosclerotic stenosis. 57 Obesity is another modifiable risk factor. As proof of principle, bariatric surgical procedures have been found to reduce the risk of stroke by 50%. 58 Intensive glucose control is generally recommended in patients with diabetes mellitus, although the benefits regarding stroke prevention are not clear. 59 
CAROTID ENDARTERECTOMY
Carotid endarterectomy, a procedure with over a half-century history, 60 is one of the most studied surgical procedures in clinical practice. As a technique that can both cause and prevent stroke, it became clear that only properly powered trials with long-duration follow-up could provide reliable evidence as to the net benefits of the procedure. Historically, randomized clinical trials have focused on treating either symptomatic or asymptomatic patients (Table 2 61-69 ).
Symptomatic Patients
There is little controversy regarding the net benefit of carotid endarterectomy in patients with symptomatic moderate-to high-grade stenosis. A key finding was that the benefits are greater for patients with higher degrees of stenosis. A meta-analysis of the 3 major clinical trials pooled individual patient data on 6092 patients and 35,000 patient-years. 70 The analysis revealed that endarterectomy was marginally beneficial for patients with 50% to 69% stenosis, with an annual absolute risk reduction of ipsilateral ischemic stroke of 4.6%. The procedure was substantially more beneficial for patients with 70% to 99% stenosis, with an annual absolute risk reduction of ipsilateral ischemic stroke of 16%. Subgroup analysis revealed the greatest benefits for men, patients 75 years of age or older, and patients randomized within 2 weeks after their last ischemic event. A separate pooled analysis of trial data from the ECST (European Carotid Surgery Trial) and the NASCET (North American Symptomatic Carotid Endarterectomy Trial) concluded that the greatest benefit from endarterectomy comes from early surgical intervention, preferably within 2 weeks. 71 Early revascularization has become commonplace, such that by 2013, 73% of patients in Florida, California, and New York had their procedure (either endarterectomy or stenting) within 14 days of stroke. 72 It should be noted, however, that early revascularization in an unstable patient with either stroke in evolution or crescendo TIA carries a high risk of stroke and death. 73 
Asymptomatic Patients
Although the effectiveness of timely endarterectomy for symptomatic high-grade carotid stenosis is well established, the benefits of endarterectomy in patients with asymptomatic carotid stenosis are less certain. Two pivotal randomized trials support endarterectomy for asymptomatic stenosis: the Asymptomatic Carotid Atherosclerosis Study (ACAS) 67 and the ACST. 69 Both trials enrolled patients with at least 60% stenosis. The ACAS monitored patients for an average of 2.7 years and found that surgical intervention resulted in an absolute reduction in the risk of ipsilateral stroke, surgical stroke, or death of 5.9%. The ACST monitored patients for an average of 9 years and found that surgical treatment resulted in an absolute reduction in the risk of any stroke or surgical death of 4.5%. Those who argue against endarterectomy in this patient population today point to the steady decline in risk of stroke in medically treated patients from the 1980s to 2010, with recent studies reporting ipsilateral stroke rates of less than 1% per year. 74 Trials are under way to clarify the role of endarterectomy compared with intensive medical therapy in patients with asymptomatic carotid stenosis. The Stent-protected Angioplasty in Asymptomatic Carotid Artery Stenosis vs. Endarterectomy (SPACE)-2 trial, with centers in Germany, Austria, and Switzerland, is comparing best medical therapy to revascularization by either endarterectomy or stenting. Slow recruitment into the SPACE-2 trial led to halting of recruitment after randomization of 513 patients; however, patients continue to be followed up for end points. 75 The National Institute of Neurological Disorders and Stroke Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2) is also comparing best medical therapy with revascularization by either endarterectomy or stenting. A total of 574 patients have been recruited as of April 13, 2017 , and recruitment and follow-up are ongoing.
CAROTID ANGIOPLASTY AND STENTING
Carotid angioplasty and stenting evolved as a potentially safer alternative to endarterectomy. A series of randomized trials ensued, mostly in patients with symptomatic stenosis 7, [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] ( Table 3 ).
Patients at High Risk for Endarterectomy
The Stenting and Angioplasty With Protection in Patients at High Risk for Endarterectomy (SAPPHIRE) trial tested whether stenting was noninferior to endarterectomy for patients at high risk for complications following endarterectomy. 83 Patients were considered at high risk for complications with endarterectomy for a number of reasons, including history of contralateral carotid occlusion or laryngeal nerve palsy, severe coronary artery disease, and radical dissection or radiation therapy to the neck. In this noninferiority trial, carotid stenting was found to be noninferior to endarterectomy for the primary end point (the composite primary end point of death, stroke, or myocardial infarction within 30 days after the intervention or ipsilateral stroke between 31 days and 1 year). 80 The 3-year rates for the secondary composite outcome of death, stroke, or myocardial infarction within 30 days or ipsilateral stroke thereafter were 26.2% for stenting and 30.3% for endarterectomy, a difference that was not significant. 83 
Symptomatic Patients
Using data from 3 randomized trials, the Carotid Stenting Trialists' Collaboration found that any stroke or death occurred significantly more often in the stenting group than the endarterectomy group (risk ratio, 1.53). 92 Using data from 4 trials, the Collaboration found that endarterectomy was clearly superior to stenting in symptomatic patients over age 70 to 74 years because of the increased risk of stroke with age for stenting but not for endarterectomy. 93 The long-term results of the Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST), which extended follow-up to 10 years, did not document a significant difference between endarterectomy and stenting when including perioperative myocardial infarction in the primary outcome. 90 Carotid stenting generally has higher procedural stroke rates than endarterectomy in randomized trials. However, the picture is slightly more complex than implied by simple counts of stroke. In the International Carotid Stenting Study (ICSS)-Magnetic Resonance Imaging Substudy, patients were scanned using 1.5-T or 3.0-T MRI at 1 to 7 days before treatment, 1 to 3 days after treatment, and 27 to 33 days after treatment. Patients who had stenting had higher lesion counts than patients who had endarterectomy, but the lesions tended to be smaller and were more likely to involve the cortex and subjacent white matter. 94 Furthermore, the total lesion volume was not significantly different between treatment groups. The functional implications of these topographic differences are unknown.
Asymptomatic Patients
About half of the patients in CREST were asymptomatic at randomization. An analysis stratified by symptomatic status revealed no significant difference for the primary end point in CREST for asymptomatic patients. 95 The Asymptomatic Carotid Trial (ACT)-1 randomized 1453 patients at standard risk of complications with endarterectomy to either endarterectomy or protected stenting. 91 There was noninferiority for the primary end point of perioperative stroke, death, or myocardial infarction or ipsilateral infarction within 1 year.
Factors Influencing the Approach to Revascularization
Many patients with carotid stenosis can undergo revascularization safely and effectively by either endarterectomy or stenting. However, some anatomic and clinical considerations should influence which approach is preferred (Table 4) . It has been argued that carotid artery stenting is less invasive, and thus one might suspect that stenting would be less expensive. However, formal cost-effectiveness studies have not confirmed this to be the case. In the ICSS, there was no significant difference in adjusted costs between endarterectomy and stenting. 96 Stenting had slightly higher costs in the CREST trial than endarterectomy. 97 
EFFECT OF EXPERIENCE ON OUTCOMES
With a caveat to be discussed subsequently, experience matters both for endarterectomy and stenting. A Canadian hospital registry found that low hospital and surgeon case volumes are risk factors for complications following endarterectomy. 98 A 10-year Maryland statewide audit found surgeon volume to inversely correlate with risk of death following endarterectomy. 99 Operator experience, as measured by average time interval between carotid stenting cases, was an independent predictor of death, stroke, or myocardial infarction in the Carotid Stenting for High Surgical-Risk Patients; Evaluating Outcomes Through the Collection of Clinical Evidence (CHOICE) registry. 100 The Nationwide Inpatient Sample found that case volume rather than operator training specialty predicted stenting outcomes. 101 The Carotid ACCULINK/ACCUNET Post Approval Trial to Uncover Rare Events (CAPTURE) 2 prospective, independently adjudicated registry reported an inverse relationship between perioperative event rates and hospital and operator volumes. 102 The Carotid Stenting Trialists' Collaboration found that the 30-day risk of stroke or death was inversely related to intrial operator volumes. 103 The caveat to operator experience being the cause of good outcomes, rather than a marker, is the given operator's threshold for operation or stent placement. For example, busy surgeons or interventionists could be busier than their colleagues in part, or in large part, because of a lower threshold to intervene. Hence, their patients would be less often symptomatic and so less often at high risk. The operative or stenting outcomes would be expected to be more favorable because of the lower threshold to intervene and not because of experience. In addition, symptomatic patients may be more likely to be referred to neurologically trained surgeons and interventionists than vascular surgeons or interventionists trained in vascular surgery or cardiology. The pool of symptomatic patients is much lower than the pool of asymptomatic patients. The ratio of the prevalence of high-grade asymptomatic carotid stenosis to recent (within 6 months) symptomatic carotid stenosis may be as high as 38:1 (estimated using a 3% prevalence of carotid stenosis in the general population over age 65 years, an estimate of 345,825 prevalent recent ischemic strokes, 104 an 8% rate of carotid stenosis among patients with ischemic stroke, 6 an estimate of 120,000 prevalent recent TIAs, 105 and a 13% rate of carotid stenosis among patients with TIA 106 ). Of course, not every patient with asymptomatic carotid stenosis will be detected, and not every patient with recent ischemic stroke will be suitable for carotid intervention because of acquired disability.
Neurosurgeons or neurointerventionists could have both a lower frequency of procedures performed overall and a higher proportion of procedures performed on a more at-risk cohort of patients. This circumstance, which is consistent with practice patterns, would be a confounder of cause and effect for experience and improved outcomes.
CONCLUSION
Patients with recent nondisabling ischemic stroke or TIA need prompt evaluation for possible high-grade carotid stenosis and if detected, referral for revascularization. Patients with asymptomatic stenosis may also be candidates for revascularization, but the net benefit is likely to be low even under the best of circumstances because unselected asymptomatic patients are at low long-term risk of stroke without revascularization. Techniques like transcranial ultrasonographic assessment for microemboli and MRI for plaque may help to stratify risk in asymptomatic patients and thereby identify patients most likely to benefit from endarterectomy or stenting, but further research is needed. Patients who are at high risk for complications with endarterectomy may be at lower risk for complications with stenting, as reported in the SAPPHIRE study. However, in these highrisk patients, neither procedure may be the preferred course of action because of an unacceptably high absolute risk of complications with either one. Making decisions regarding whether and how to revascularize patients is only part of the management of carotid stenosis and should not distract from the importance of control of medical risk factors, including hypertension, hyperlipidemia, and smoking cessation. 
